缺氧实体瘤新型诊疗一体化药物[64Cu][Cu(elesclomol)]的体外与体内表征
本研究改进64Cu生产方法并合成[64Cu][Cu(ES)],在22Rv1、PC3前列腺癌细胞和U-87MG胶质母细胞瘤细胞中评估其体外疗效,在22Rv1异种移植瘤小鼠中评估体内疗效,并与[64Cu][Cu(ATSM)]和[64Cu]CuCl2比较,结果显示[64Cu][Cu(ES)]降低细胞存活和抑制肿瘤生长的效果更优,[64Cu][Cu(ES)]-PET检测肿瘤缺氧可行,并意外发现脑内摄取。
要点
- 缺氧增加[64Cu][Cu(ES)]和[64Cu][Cu(ATSM)]的细胞摄取和内化。
- [64Cu][Cu(ES)]在体外和体内降低细胞存活、抑制肿瘤生长均优于[64Cu][Cu(ATSM)]和[64Cu]CuCl2。
- [64Cu][Cu(ES)]-PET检测肿瘤缺氧可行,并意外发现脑内摄取。
核心结论
- 首次实现ES与[64Cu]CuCl2放射性标记得到[64Cu][Cu(ES)]。
- 与[64Cu][Cu(ATSM)]和[64Cu]CuCl2相比,[64Cu][Cu(ES)]显示出更优的治疗效果,且[64Cu][Cu(ES)]-PET检测肿瘤缺氧可行。
- [64Cu][Cu(ES)]是用于缺氧实体瘤的有前景的诊疗一体化药物。
研究设计与样本
- 采用12 MeV生物医学回旋加速器通过64Ni(p,n)64Cu反应生产Cu-64,随后合成[64Cu]CuCl2、[64Cu][Cu(ATSM)]和[64Cu][Cu(ES)]。
- 体外用克隆形成实验在常氧和缺氧的22Rv1和PC3前列腺癌细胞及U-87MG胶质母细胞瘤细胞中评估治疗效果,并分析细胞摄取和内化。
- 体内在BALB/cAnN-Foxn1nu/nu/Rj小鼠的22Rv1异种移植瘤中评估单次或多次给药的治疗效果,随后在22Rv1和U-87MG异种移植瘤中用PET评估检测肿瘤缺氧的可行性。
主要发现
- 体外和体内研究显示[64Cu][Cu(ES)]降低细胞存活和抑制肿瘤生长比[64Cu][Cu(ATSM)]和[64Cu]CuCl2更有效。
- 缺氧增加[64Cu][Cu(ES)]和[64Cu][Cu(ATSM)]的细胞摄取和内化。
- [64Cu][Cu(ES)]-PET检测肿瘤缺氧可行,并意外发现脑内摄取。
关键数值与推荐
- Cu-64通过12 MeV回旋加速器64Ni(p,n)64Cu反应生产。
- 体外治疗效果在常氧和缺氧的22Rv1、PC3和U-87MG细胞中用克隆形成实验评估。
- 体内治疗效果在22Rv1异种移植瘤中评估单次或多次给药,PET在22Rv1和U-87MG异种移植瘤中评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hypoxic tumors are associated with therapy resistance and poor cancer prognosis, but methods to detect and counter tumor hypoxia remain insufficient. Our purpose was to investigate 64Cu(II)-elesclomol ([64Cu][Cu(ES)]) as a novel theranostic agent for hypoxic tumors, by implementing an improved production method and assessing its therapeutic and diagnostic potential compared to the established Cu-64 radiopharmaceuticals [64Cu]CuCl2 and [diacetyl-bis(N4-methylthiosemicarbazone) [64Cu][Cu(ATSM)]. METHODS: Cu-64 was produced using a biomedical cyclotron at 12 MeV with the reaction 64Ni(p,n)64Cu, followed by synthesis of [64Cu]CuCl2, [64Cu][Cu(ATSM)], and [64Cu][Cu(ES)]. In vitro therapeutic effects were assessed in both normoxic and hypoxic cells (22Rv1 and PC3 prostate cancer cells, and U-87MG glioblastoma cells) using the clonogenic assay and analyzing cellular uptake and internalization. In vivo therapeutic effects were assessed in 22Rv1 xenografts in BALB/cAnN-Foxn1nu/nu/Rj mice receiving a single or multiple doses of radiopharmaceutical, before their feasibility to detect tumor hypoxia was assessed by positron emission tomography (PET) in 22Rv1 and U-87MG xenografts. RESULTS: In vitro and in vivo studies demonstrated that [64Cu][Cu(ES)] reduced cell survival and inhibited tumor growth more effectively than [64Cu][Cu(ATSM)] and [64Cu]CuCl2. Hypoxia increased the cellular uptake and internalization of [64Cu][Cu(ES)] and [64Cu][Cu(ATSM)]. [64Cu][Cu(ES)]-PET tumor hypoxia detection was feasible and also revealed an unexpected finding of uptake in the brain. CONCLUSION: To the best of our knowledge, this is the first time that ES is radiolabeled with [64Cu]CuCl2 to [64Cu][Cu(ES)]. We demonstrated superior therapeutic effects of [64Cu][Cu(ES)] compared to [64Cu][Cu(ATSM)] and [64Cu]CuCl2 and that [64Cu][Cu(ES)]-PET is feasible. [64Cu][Cu(ES)] is a promising theranostic agent for hypoxic solid tumors.
引用
- Liu T, Dahle MA, Lystad MH, et al. In vitro and in vivo characterization of [64Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors. Eur J Nucl Med Mol Imaging. 2023. PMID: 37382663. doi:10.1007/s00259-023-06310-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。